Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3 - Slamon, D J; Neven, P; Chia, S (J Clin Oncol, 2018)